肺动脉高压与免疫炎症

王雪芳; 谢萍

doi:10.13201/j.issn.1001-1439.2019.05.003

肺动脉高压与免疫炎症

王雪芳¹,
谢萍^2, ,

- 1. 甘肃中医药大学(兰州, 730000);
- 2. 甘肃省人民医院

详细信息

通讯作者: 谢萍,E-mail:wx648842179@163.com

中图分类号: R544.1

收稿日期: 2018-10-05

修回日期: 2018-11-24

Immune and inflammatory mechanisms in pulmonary arterial hypertension

WANG Xuefang¹,
XIE Ping^2, ,

- 1. Gansu University of Chinese Medicine, Gansu, 730000, China;
- 2. Gansu Provincial Hospital

More Information

Corresponding author: XIE Ping, E-mail: wx648842179@163.com

Received Date: 05 October 2018

Revised Date: 24 November 2018

摘要

摘要: 肺动脉高压是多种病因引起的起病隐匿、病死率高、预后差的慢性进行性疾病，其发病机制尚未完全清楚。免疫炎症在肺动脉高压发生过程中起着重要作用。本文就肺动脉高压形成过程中免疫细胞、细胞因子及趋化因子的作用等进行总结，作一综述。
- 肺动脉高压 /
- 免疫炎症 /
- 肺血管重构
Abstract: Pulmonary arterial hypertension is a chronic disease caused by a variety of causes with hidden onset, high mortality and poor prognosis.Its pathogenesis has not yet fully understood.Immune inflammation plays an important role in the development of pulmonary arterial hypertension.This article summarizes the effect of immune cells, cytokines and chemokines in the process of pulmonary arterial hypertension.
- pulmonary arterial hypertension /
- immune and inflammatory /
- pulmonary vascular remodeling

HTML全文

参考文献(52)

[1]	Kovacs G, Dumitrescu D, Barner A, et al.Definition, clinical classification and initial diagnosis of pulmonary hypertension:updated recommendations from the cologne consensus conference 2018[J].Int J Cardiol, 2018, 272S:11-19.
[2]	Lau EMT, Marc H, Celermajer DS.Early detection of pulmonary arterial hypertension[J].Nat Rev Cardiol, 2015, 12(3):143-155.
[3]	Price LC, Wort SJ, Perros F, et al.Inflammation in pulmonary arterial hypertension[J].Chest, 2012, 141(1):210-221.
[4]	Emt L, Giannoulatou E, Celermajer DS, et al.Epidemiology and treatment of pulmonary arterial hypertension[J].Nat Rev Cardiol, 2017, 14(10):603.
[5]	Ataya A, Patel S, Cope J, et al.Pulmonary arterial hypertension and associated conditions[J].Dis Mon, 2016, 62(11):379-402.
[6]	Price LC, Shao D, Meng C, et al.Dexamethasone induces apoptosis in pulmonary arterial smooth muscle cells[J].Respir Res, 2015, 16(1):1-16.
[7]	Tang B, Chen GX, Liang MY, et al.Ellagic acid prevents monocrotaline-induced pulmonary artery hypertension via inhibiting NLRP3 inflammasome activation in rats[J].Int J Cardiol, 2015, 180:134-141.
[8]	Tuder RM, Groves B, Badesch DB, et al.Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension[J].Am J Pathol, 1994, 144(2):275-285.
[9]	Bonnet S, Rochefort G, Sutendra G, et al.The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted[J].Proc Natl Acad Sci USA, 2007, 104(27):11418-11423.
[10]	Hassoun PM, Luc M, Barberà JA, et al.Inflammation, growth factors, and pulmonary vascular remodeling[J].J Am Coll Cardiol, 2009, 54(1):S10-S19.
[11]	周高亮, 冯俊, 张静.低氧对肺动脉血管平滑肌细胞Kv通道电流的影响[J].临床心血管病杂志, 2018, 34(2):184-188.
[12]	Bushdid PB, Osinska H, Waclaw RR, et al.NFATc3 and NFATc4 Are Required for cardiac Development and mitochondrial function[J].Circ Res, 2003, 92(12):1305-1313.
[13]	Daley E, Emson C, Guignabert C, et al.Pulmonary arterial remodeling induced by a Th2 immune response[J].J Exp Med, 2008, 205(2):361-372.
[14]	Kherbeck N, Tamby MC, Bussone G, et al.The Role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension[J].Clin Rev Allergy Immunol, 2013, 44(1):31-38.
[15]	Silvia U, Laima TS, Huber LC, et al.Peripheral blood B lymphocytes derived from patients with idiopathic pulmonary arterial hypertension express a different RNA pattern compared with healthy controls:a cross sectional study[J].Respir Res, 2008, 9(1):20.
[16]	Gashouta MA, Humbert M, Hassoun PM.Update in systemic sclerosis-associated pulmonary arterial hypertension[J].Presse Med, 2014, 43(10):e293-e304.
[17]	Negi VS, Tripathy NK, Misra R, et al.Antiendothelial cell antibodies in scleroderma correlate with severe digital ischemia and pulmonary arterial hypertension[J].J Rheumatol, 1998, 25(3):462-466.
[18]	Okano Y, Steen VD, Medsger TA Jr.Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis[J].Arthritis Rheum, 2010, 35(1):95-100.
[19]	Pinto RF, Higuchi ML, Aiello VD.Decreased numbers of T-lymphocytes and predominance of recently recruited macrophages in the walls of peripheral pulmonary arteries from 26 patients with pulmonary hypertension secondary to congenital cardiac shunts[J].Cardiovasc Pathol, 2004, 13(5):268-275.
[20]	Minamino T, Christou H, Hsieh CM, et al.Targeted Expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia[J].Proc Nat Acad Sci USA, 2001, 98(15):8798-8803.
[21]	Miyata M, Sakuma F, Yoshimura A, et al.Pulmonary hypertension in rats.1.Role of bromodeoxyuridine-positive mononuclear cells and alveolar macrophages[J].Int Arch Allergy Immunol, 1995, 1108(3):281-286.
[22]	Itoh T, Nagaya N, Ishibashiueda H, et al.Increased plasma monocyte chemoattractant protein-1 level in idiopathic pulmonary arterial hypertension[J].Respirology, 2010, 11(2):158-163.
[23]	Tian W, Jiang X, Tamosiuniene R, et al.Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension[J].Sci Translat Med, 2013, 5(200):200ra117.
[24]	Hamada H, Terai M, Kimura H, et al.Increased expression of mast cell chymase in the lungs of patients with congenital heart disease associated with early pulmonary vascular disease[J].Am J Respir Crit Care Med, 1999, 160(4):1303-1308.
[25]	Heath D, Yacoub M.Lung mast cells in plexogenic pulmonary arteriopathy[J].J Clin Pathol, 1991, 44(12):1003-1006.
[26]	Miyata M, Sakuma F, Ito M, et al.Athymic nude rats develop severe pulmonary hypertension following monocrotaline administration[J].Int Arch Allergy Immunol, 2000, 121(3):246-252.
[27]	He S, Peng Q, Walls AF.Potent induction of a neutrophil and eosinophil-rich infiltrate in vivo by human mast cell tryptase:selective enhancement of eosinophil recruitment by histamine[J].J Immunol, 1997, 159(12):6216-6225.
[28]	王俊贤, 马倍, 刘珍君, 等.过表达ACE2基因的骨髓间充质干细胞对肺动脉高压大鼠的干预作用[J].临床心血管病杂志, 2018, 34(4):396-402.
[29]	Miyazaki M, Takai S, Jin D, et al.Pathological roles of angiotensin II produced by mast cell chymase and the effects of chymase inhibition in animal models[J].Pharmacol Ther, 2006, 112(3):668-676.
[30]	Banasová A, Maxová H, Hampl V, et al.Prevention of mast cell degranulation by disodium cromoglycate attenuates the development of hypoxic pulmonary hypertension in rats exposed to chronic hypoxia[J].Respiration, 2008, 76(1):102-107.
[31]	Gambaryan N, Perros F, Montani D, et al.Targeting of c-kit+ haematopoietic progenitor cells prevents hypoxic pulmonary hypertension[J].Eur Respir J, 2011, 37(6):1392-1399.
[32]	Humbert M, Monti G, Brenot F, et al.Increased interleukin-1 and intetieukin-6 serum concentrations in severe primary pulmonary hypertension[J].Am J Respir Crit Care Med, 1995, 151(5):1628-1631.
[33]	Lawrie A, Waterman E, Southwood M, et al.Evidence of a role for osteoprotegerin in the pathogenesis of pulmonary arterial hypertension[J].Am J Pathol, 2008, 172(1):256-264.
[34]	Voelkel NF, Tuder RM, Bridges J, et al.Interleukin-1 receptor antagonist treatment reduces pulmonary hypertension generated in rats by monocrotaline[J].Am J Respir Cell Mol Biol, 1994, 11(6):664-675.
[35]	Soon E, Holmes AM, Treacy CM, et al.Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension[J].Circulation, 2010, 122(9):920-927.
[36]	Steiner MK, Syrkina OL, Kolliputi N, et al.Interleukin-6 Overexpression Induces Pulmonary Hypertension[J].Circ Res, 2009, 104(2):236-244.
[37]	Vaillancourt M, Ruffenach G, Meloche J, et al.Adaptation and remodelling of the pulmonary circulation in pulmonary hypertension[J].Can J Cardiol, 2015, 31(4):407-415.
[38]	Sutendra G, Dromparis P, Bonnet S, et al.Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNFα contributes to the pathogenesis of pulmonary arterial hypertension[J].J Mol Med, 2011, 89(8):771-783.
[39]	Crosswhite P, Chen K, Sun Z.AAV Delivery of TNF-α shRNA attenuates cold-induced pulmonary hypertension and pulmonary arterial remodeling[J].Hypertension, 2014, 64(5):1141-1150.
[40]	Wang Q, Zuo XR, Wang YY, et al.Monocrotaline-induced pulmonary arterial hypertension is attenuated by TNF-α antagonists via the suppression of TNF-α expression and NF-κB pathway in rats[J].Vasc Pharmacol, 2013, 58(1-2):71-77.
[41]	Xu G, Barrios-Rodiles M, Jerkic M, et al.Novel protein interactions with endoglin and activin receptor-like kinase 1:potential role in vascular networks[J].Mol Cell Proteomics, 2014, 13(2):489-502.
[42]	Marshall JD, Sauler M, Tonelli A, et al.Complexity of macrophage migration inhibitory factor (MIF) and other angiogenic biomarkers profiling in pulmonary arterial hypertension[J].Pulm Circ, 2017, 7(3):730-733.
[43]	Dubrock HM, Rodriguezlopez JM, Levarge BL, et al.Macrophage migration inhibitory factor as a novel biomarker of portopulmonary hypertension[J].Pul Circ, 2016, 6(4):498-507.
[44]	Morane LH, Ly T, Nicolas R, et al.Proinflammatory signature of the dysfunctional endothelium in pulmonary hypertension.role of the macrophage migration inhibitory factor/CD74 complex[J].Am J Respir Crit Care Med, 2015, 192(8):983-997.
[45]	Itoh A, Nishihira J, Makita H, et al.Effects of IL-1beta, TNF-alpha, and macrophage migration inhibitory factor on prostacyclin synthesis in rat pulmonary artery smooth muscle cells[J].Respirology, 2003, 8(4):467-472.
[46]	Zhang B, Luo Y, Liu ML, et al.Macrophage migration inhibitory factor contributes to hypoxic pulmonary vasoconstriction in rats[J].Microvasc Res, 2012, 83(2):205-212.
[47]	Hassoun PM, Mouthon L, Barberà JA, et al.Inflammation, growth factors, and pulmonary vascular remodeling[J].J Am Coll Cardiol, 2009, 54(1):S10-S19.
[48]	Sun H, Choo-wing R, Sureshbabu A, et al.A critical regulatory role for macrophage migration inhibitory factor in hyperoxia-induced injury in the developing murine lung[J].PLoS One, 2013, 8(4):e60560.
[49]	Sanchez O, Marcos E, Perros F, et al.Role of Endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension[J].Am J Respir Crit Care Med, 2007, 176(176):1041-1047.
[50]	Dorfmüller P, Zarka V, Durand-Gasselin I, et al.Chemokine RANTES in severe pulmonary arterial hypertension[J].Am J Respir Crit Care Med, 2002, 165(4):534-539.
[51]	Young KC, Torres E, Hatzistergos KE, et al.Inhibition of the SDF-1/CXCR4 axis attenuates neonatal hypoxia-induced pulmonary hypertension[J].Circ Res, 2009, 104(11):1293-1301.
[52]	David M, Frédéric P, Natalia G, et al.C-kit-positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension[J].Am J Respir Crit Care Med, 2011, 184(1):116-123.